%PDF-1.4
%
65 0 obj
<>
endobj
62 0 obj
<>
endobj
123 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2005-01-10T11:25:56Z
2024-03-29T03:20:14-07:00
QuarkXPressª: AdobePS 8.8.0 (301)
2024-03-29T03:20:14-07:00
application/pdf
Heather
2004-161.feb
uuid:dfef4eb2-1dd1-11b2-0a00-9109276d7200
uuid:dfef4eb5-1dd1-11b2-0a00-b80000000000
endstream
endobj
51 0 obj
<>
endobj
52 0 obj
<>
endobj
66 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 37 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 39 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 41 0 R/Type/Page>>
endobj
23 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 43 0 R/Type/Page>>
endobj
34 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 45 0 R/Type/Page>>
endobj
141 0 obj
[145 0 R]
endobj
142 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
13.5 787.5 585 -783 re
W n
q
0 792.03 612 -792 re
W n
0 0 0 1 K
/GS1 gs
53.964 76.5 m
558.972 76.5 l
S
0 0 0 0 k
52.822 69.665 64.178 -15.665 re
f*
BT
0 0 0 1 k
/T1_0 1 Tf
8 0 0 8 53.8216 56.7343 Tm
(324)Tj
ET
0 0 0 0 k
356 69.665 203 -15.665 re
f*
BT
0 0 0 1 k
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 424.3613 56.7343 Tm
(The Journal of Rheumatology 2005; 32:2)Tj
/T1_1 1 Tf
0 Tc -44.1117 85.0369 Td
(1996;87:2095-147. )Tj
-0.00011 Tc -2 -1.25 Td
[(10.)-750.1 (Eastgate JA, Symons JA, Nigel CW)91.7 (, et al. Correlation of plasma)]TJ
2 -1.25 Td
(interleukin 1 levels and disease activity in rheumatoid arthritis.)Tj
0 -1.25 TD
(Lancet 1988;2:706-9. )Tj
-1.9631 -1.25 Td
[(1)36.8 (1)-0.1 (.)-750.1 (Peck )17.7 (W)110.9 (A, )17.7 (W)79.9 (oods )17.7 (WL. )17.7 (The cells of bone. In: Riggs BL, Melton LJ)]TJ
1.9631 -1.25 Td
[(III, editors. Osteoporosis: etiology)64.8 (, diagnosis, and management.)]TJ
T*
[(New )36.8 (Y)99.8 (ork: Raven Press; 1988:1-44. )]TJ
-2 -1.25 Td
[(12.)-750.1 (Boyce BF)79.7 (, )54.8 (Aufdemorte )17.7 (TB, Garrett IR, )36.8 (Y)99.8 (ates )54.8 (AJ, Mundy GR.)]TJ
2 -1.25 Td
[(Ef)17.7 (fects of interleukin-1 on bone turnover in normal mice.)]TJ
T*
[(Endocrinology 1989;125:1)36.8 (142-50. )]TJ
-2 -1.25 Td
[(13.)-750.1 (Sabatini M, Boyce B, )54.8 (Aufdemorte )17.7 (T)74 (,)-0.1 ( Bonewald L, Mundy GR.)]TJ
2 -1.25 Td
(Infusions of recombinant human interleukins 1)Tj
/T1_2 1 Tf
0 Tc 0 Tw 18.8692 0 Td
(\002)Tj
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw 0.9059 0 Td
(and 1\247 cause)Tj
-19.775 -1.25 Td
[(hypercalcemia in normal mice. Proc Natl )54.8 (Acad Sci USA)]TJ
0 Tc T*
(1988;85:5235-9. )Tj
-0.00011 Tc -2 -1.25 Td
[(14.)-750.1 (Morony S, Capparelli C, Lee R, et al. )54.8 (A)-220.1 (chimeric form of)]TJ
2 -1.25 Td
(osteoprotegerin inhibits hypercalcemia and bone resorption induced)Tj
T*
[(by IL-1\247, )17.7 (TNF-)]TJ
/T1_2 1 Tf
0 Tc 0 Tw [-0.2 (\002)]TJ
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw [0.1 (, PTH, PTHrP)110.7 (, and 1,25\(OH\)2D3. J Bone Miner)]TJ
0 Tc 0.0001 -1.25 Td
(Res 1999;14:1478-85. )Tj
-0.00011 Tc -2 -1.25 Td
[(15.)-750.1 (Niki )36.8 (Y)128.9 (,)-0.1 ( )36.8 (Y)99.8 (amada H, Seki S, et al. Macrophage- and neutrophil-)]TJ
2 -1.25 Td
(dominant arthritis in human IL-1)Tj
/T1_2 1 Tf
0 Tc 0 Tw [-0.2 (\002)]TJ
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw 14.1687 0 Td
(transgenic mice. J Clin Invest)Tj
0 Tc -14.1687 -1.25 Td
[(2001;107:1)36.9 (127-35. )]TJ
-0.00011 Tc -2 -1.25 Td
[(16.)-750.1 (Parfitt )54.8 (AM, Drezner MK, Gloroeux FH, et al. Bone)]TJ
2 -1.25 Td
(histomorphometry: standardization of nomenclature, symbols, and)Tj
0 Tc T*
(units. J Bone Miner Res 1987;2:595-610. )Tj
-0.00011 Tc -2 -1.25 Td
[(17.)-750.1 (Miyamoto )17.7 (T)74 (,)-0.1 ( Ohneda O, )54.8 (Arai F)79.7 (, et al. Bifurcation of osteoclasts and)]TJ
2 -1.25 Td
(dendritic cells from common progenitors. Blood 2001;98:2544-54. )Tj
-2 -1.25 Td
[(18.)-750.1 (Jimi E, Nakamura I, Duong L)91.7 (T)74 (, et al. Interleukin 1 induces)]TJ
2 -1.25 Td
(multinucleation and bone-resorbing activity of osteoclasts in the)Tj
T*
(absence of osteoblasts/stromal cells. Exp Cell Res 1999;247:84-93. )Tj
-2 -1.25 Td
[(19.)-750.1 (Kobayashi K, )17.7 (T)69.9 (akahashi N, Jimi E, et al. )17.7 (T)35 (umor necrosis factor )]TJ
/T1_2 1 Tf
0 Tc 0 Tw 27.8192 0 Td
(\002)Tj
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw -25.8192 -1.25 Td
[(stimulates osteoclast dif)17.7 (ferentiation by a mechanism independent of)]TJ
T*
(the ODF/RANKL-RANK interaction. J Exp Med 2000;191:275-85. )Tj
-2 -1.25 Td
[(20.)-750.1 (W)79.9 (erman )54.8 (A, )17.7 (W)79.9 (erman-V)110.8 (enkert R, )17.7 (White R, et al. )17.7 (The precursor form)]TJ
2 -1.25 Td
(of IL-1 alpha is an intracrine proinflammatory activator of)Tj
T*
[(transcription. Proc Natl )54.8 (Acad Sci USA)-220.1 (2004;101:2434-9. )]TJ
-2 -1.25 Td
[(21.)-750.1 (Canalis E. Interleukin-1 has independent ef)17.7 (fects on DNA)-220.2 (and)]TJ
2 -1.25 Td
(collagen synthesis in cultures of rat calvariae. Endocrinology)Tj
0 Tc T*
[(1986;1)36.9 (18:74-81. )]TJ
-0.00011 Tc -2 -1.25 Td
[(22.)-750.1 (Kuroki )17.7 (T)74 (, Shingu M, Koshihara )36.8 (Y)128.9 (, Nobunaga M. Ef)17.7 (fect of cytokines)]TJ
2 -1.25 Td
(on alkaline phosphatase and osteocalcin production, calcification)Tj
T*
(and calcium release by human osteoblastic cells. Br J Rheumatol)Tj
0 Tc T*
(1994;33:224-30. )Tj
-0.00011 Tc 31 51.25 Td
[(23.)-750.1 (Katz MS, Gutierrez GE, Mundy GR, Hymer )17.7 (TK, Caufiels MP)110.7 (,)]TJ
2 -1.25 Td
[(McKee RL. )17.7 (T)35 (umor necrosis factor and interleukin 1 inhibit)]TJ
T*
(parathyroid hormone-responsive adenylate cyclase in clonal)Tj
T*
(osteoblast-like cells by downregulating parathyroid hormone)Tj
T*
(receptors. J Cell Physiol 1992;153:206-13. )Tj
-2 -1.25 Td
[(24.)-750.1 (Moss DW)91.7 (, Eaton H, Smith JK, )17.7 (Whitby LG. )54.8 (Association of)]TJ
2 -1.25 Td
[(inor)17.7 (ganic-pyrophosphatase activity with human alkaline phosphatase)]TJ
T*
(preparations. Biochem J 1967;102:53-7. )Tj
-2 -1.25 Td
[(25.)-750.1 (Anderson HC. Molecular biology of matrix vesicles. Clin Orthop)]TJ
0 Tc 2 -1.25 Td
(1995;314:266-80. )Tj
-0.00011 Tc -2 -1.25 Td
[(26.)-750.1 (Goldring SR. Pathogenesis of bone erosions in rheumatoid arthritis.)]TJ
2 -1.25 Td
(Curr Opin Rheumatol 2002;14:406-10. )Tj
-2 -1.25 Td
[(27.)-750.1 (Saville PD, Kharmosh O. Osteoporosis of rheumatoid arthritis:)]TJ
2 -1.25 Td
[(Influence of age, sex, and corticosteroids. )54.8 (Arthritis Rheum)]TJ
0 Tc T*
(1967;10:423-30. )Tj
-0.00011 Tc -2 -1.25 Td
[(28.)-750.1 (Sambrook PN, )54.8 (Ansell BM, Foster S, Gumpel JM, Hesp R, Reeve J.)]TJ
2 -1.25 Td
(Bone turnover in early rheumatoid arthritis: 2. Longitudinal bone)Tj
0 Tc T*
[(density studies. )54.8 (Ann Rheum Dis 1985;44:580-4. )]TJ
-0.00011 Tc -2 -1.25 Td
[(29.)-750.1 (Laan RF)79.7 (, Buijs )17.7 (WC, )17.7 (V)110.8 (erbeek )54.8 (AL, et al. Bone mineral density in)]TJ
2 -1.25 Td
(patients with recent onset rheumatoid arthritis: Influence of disease)Tj
T*
[(activity and functional capacity)64.8 (. )54.8 (Ann Rheum Dis 1993;52:21-6. )]TJ
-2 -1.25 Td
[(30.)-750.1 (W)79.9 (einreb M, Rodan GA, )17.7 (Thompson DD. Osteopenia in the)]TJ
2 -1.25 Td
(immobilized rat hind limb is associated with increased bone)Tj
T*
(resorption and decreased bone formation. Bone 1989;10:187-94. )Tj
-2 -1.25 Td
[(31.)-750.1 (Rantakokko J, Uusitalo H, Jamsa )17.7 (T)74 (,)-0.1 ( )17.7 (T)35 (uukkanen J, )54.8 (Aro HT)73.9 (, )17.7 (V)59.8 (uorio)]TJ
2 -1.25 Td
(E. Expression profiles of mRNAs for osteoblast and osteoclast)Tj
T*
(proteins as indicators of bone loss in mouse immobilization)Tj
T*
(osteopenia model. J Bone Miner Res 1999;14:1934-42. )Tj
-2 -1.25 Td
[(32.)-750.1 (Compston JE, )17.7 (V)110.8 (edi S, Mellish R)54.8 (W)91.8 (, Croucher P)110.7 (, O\325Sullivan MM.)]TJ
2 -1.25 Td
(Reduced bone formation in non-steroid treated patients with)Tj
0 Tc T*
[(rheumatoid arthritis. )54.8 (Ann Rheum Dis 1989;48:483-7. )]TJ
-0.00011 Tc -2 -1.25 Td
[(33.)-750.1 (Compston JE, )17.7 (V)110.8 (edi S, Croucher PI, Garrahan NJ, O\325Sullivan MM.)]TJ
2 -1.25 Td
(Bone turnover in non-steroid treated patients with rheumatoid)Tj
0 Tc T*
[(arthritis. )54.9 (Ann Rheum Dis 1994; 53:163-6. )]TJ
-0.00011 Tc -2 -1.25 Td
[(34.)-750.1 (Hirayama )17.7 (T)74 (, Danks L, Sabokbar )54.8 (A, )54.8 (Athanasou NA. Osteoclast)]TJ
2 -1.25 Td
(formation and activity in the pathogenesis of osteoporosis in)Tj
T*
(rheumatoid arthritis. Rheumatology Oxford 2002;41:1232-9. )Tj
ET
0 0 0 0 k
/GS0 gs
103.631 82.25 407.5 -10.833 re
f*
0.5 w
/GS1 gs
103.631 82.25 407.5 -10.833 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_3 8 Tf
108.828 74 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2005. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_4 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
45 0 obj
<>stream
8;Z\7Mf+/4%*S\N@")agL`M7t!%i$@G#?4.3%dD8EBVQ
&W"q-!cD6&rn,YF&coZQFI0:,\M)%W#'D;n(!6>#4OG"B#=re='cOr^AQ,[CP!'MY
4sqH*^-%`9BqVQ\8k_`4>Fj8HchqlnbmCYNEit>e7E&2J0E/qM#,Sse`/t^]R;--"
hSetAH^tbLbQ;4K5p\^G`HrQbkjZMS(q!Ob#Pp32W%MocYhs!BWQm1Sft@9KPn$IX
E6.$!lMLb1dGnjYM*Bp[W4Fo/TbussV1/&m16E6c_ZUIE>fcF>MZ0i
PWU=nb`eY.&bOB'YA_B@d5JQfEXL@ko_jX^.or`RZ!t[*%soOU]=a^6.9m[=Pf@Xf
r1E0KJQD]0p_j-_n=#@~>
endstream
endobj
49 0 obj
[/Indexed/DeviceRGB 255 48 0 R]
endobj
48 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
69 0 obj
<>
endobj
82 0 obj
<>
endobj
74 0 obj
<>
endobj
112 0 obj
<>
endobj
128 0 obj
<>
endobj
68 0 obj
<>
endobj
72 0 obj
<>
endobj
73 0 obj
<>stream
HTPn0StbhCҢnm_Iqt<;~DL0#.~
a8
hUTVY